Cochrane review: Dipyridamole for preventing major vascular events in patients with vascular disease

Stroke

Volumn 34, Issue 8, 2003, Pages 2072-2080

  De Schryver, E L L M ^b   Algra, A ^a   Van Gijn, J ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NONE

Author keywords

Dipyridamole; Stroke; Vascular diseases

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; DIPYRIDAMOLE; SULFINPYRAZONE;

ARTERY DISEASE; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HUMAN; METHODOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; STATISTICAL ANALYSIS; STROKE; TREATMENT OUTCOME; VASCULAR DISEASE;

CEREBROVASCULAR ACCIDENT; DEATH, SUDDEN, CARDIAC; DIPYRIDAMOLE; DRUG THERAPY, COMBINATION; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; TREATMENT OUTCOME; VASCULAR DISEASES;

EID: 0041621474     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000082381.23938.0E     Document Type: Review

References (32)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
2. Algra A, van Gijn J, Koudstaal PJ. Secondary prevention after cerebral ischaemia of presumed arterial origin: is aspirin still the touchstone? J Neurol Neurosurg Psychiatry. 1999;66:557-559.
3. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplalelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
4. Algra A, van Gijn J. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J Neurol Neurosurg Psychiatry. 1996; 60:197-199.
5. Warlow C. Secondary prevention of stroke. Lancet. 1992;339:724-727.
6. Algra A, van Gijn J. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry. 1999;66:255. Letter.
7. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom Transient Ischaemic Attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry. 1991;54:1044-1054.
8. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke N Engl J Med. 1991;325:1261-1266.
9. The ESPS-2 Group. European Stroke Prevention Study 2: efficacy and safety data. J Neurol Sci. 1997;151(suppl):S1-S77.
10. Guiraud-Chaumeil B, Rascol A, David J, Boneu B, Clanet M, Bierme R. Prévention des récidives des accidents vasculaires cérébraux ischémiques par les anti-agrégants plaquettaires: résultats d'un essai thérapeutique controlé de 3 ans. Rev Neurol Paris. 1982;138:367-385.
11. Bousser MG, Eschwege E, Haguenau M, Lefaucconnier JM, Thibult N, Touboul D, et al. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke. 1983;14:5-14.
12. American-Canadian Co-operative Study Group. Persantine Aspirin Trial in cerebral ischemia. part II: endpoint results. Stroke. 1985;16:406-415.
13. 13a. Kaye J. A trial to evaluate the relative roles of dipyridamole and aspirin in the prevention of deep vein thrombosis in stroke patients. Bracknell. Berkshire, UK: Boehringer Ingelheim: 1990. Internal report.
14. 13b. Middleton DA, Deichsel G. The prophylaxis of thrombosis in new arteriovenous dialysis shunts in the arm by low-dose acetylsalicylic acid and dipyridamole. Berlin. Germany: Boehringer Ingelheim: 1992. Internal report.
15. Igloe MC. Treatment of angina pectoris with dipyridamole: a double-blind study. J Am Geriatr Soc. 1970;18:233-241.
16. Caneschi S, Bonaventi C, Finzi F. Ischemic cerebrovascular disease: treatment with various anti-platelet aggregation drugs: clinical follow-up of 80 patients (22-34 months). Minerva Med. 1985;76:1933-1943.
17. De Schryver ELLM, on behalf of the European/Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) Group. Design of ESPRIT: an international randomized trial for secondary prevention after non-disabling cerebral ischaemia of arterial origin. Cerebrovasc Dis. 2000;10:147-150.
18. De Schryver ELLM, on behalf of the European/Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) Group. ESPRIT: protocol change. Cerebrovasc Dis. 2001;11:286.
19. ESPS Group. European Stroke Prevention Study. Stroke. 1990;21: 1122-1130.
20. Acheson J, Danta G, Hutchinson EC. Controlled trial of dipyridamole in cerebral vascular disease. Br Med J. 1969;I:614-615.
21. Sbar S, Schlant RC. Dipyridamole in the treatment of angina pectoris: a double-blind evaluation. JAMA. 1967;201:865-867.
22. Becker MC. Angina pectoris: a double blind study with dipyridamole. J Newark Beth Israel Hospital. 1967;18:88-94.
23. The DAMAD Study Group. Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy: a multicenter randomized controlled clinical trial. Diabetes. 1989;38:491-498.
24. Hess H, Mietaschk A, Deichsel G. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease: a prospective double-blind arteriographically controlled trial. Lancet. 1985; 1:415-419.
25. Libretti A, Catalano M. Treatment of claudication with dipyridamole and aspirin. Int J Clin Pharmacol Res. 1986;14:207-209.
26. Misra NP, Bhargava RK, Manoria PC. Comparative trials of sulphinpyrazone and aspirin + dipyridamole in acute myocardial infarction. Curr Ther Res Clin Exp. 1983;34:558-566.
27. Schoop W, Levy H, Schoop B, Gaentzsch A. Experimentelle und klinische Studien zu der sekundären Prävention der peripheren Arteriosklerose. Bollinger A, Rhyner K, eds. New York, NY: Georg Thieme Verlag Stuttgart; 1983:49-58.
28. Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM. Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study. Kidney Int. 1994;45:1477-1483.
29. Wirecki M. Treatment of angina pectoris with dipyridamole: a long-term double blind study. J Chron Dis. 1967;20:139-145.
30. FitzGerald GA, Dipyridamole. N Engl J Med. 1987;316:1247-1257.
31. Tijssen JG. Low-dose and high-dose acetylsalicylic acid, with and without dipyridamole: a review of clinical trial results. Neurology. 1998; 51:S15-S16.
32. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest. 2001;119: 300S-320S.